Abstract
Background: MiRNAs are promising biomarkers for early ESCC detection and prognostic prediction. This study aimed to explore the potential biomarkers and molecular pathogenesis in early diagnosis of esophageal squamous cell carcinoma (ESCC).
Results: 48 differentially expressed miRNAs (DEMs) and 1319 differentially expressed genes (DEGs) were identified between 94 ESCC tissues and 13 normal esophageal tissues in TCGA. Among 6558 target genes of the 48 DEMs, 400 are also in 1319 DEGs. Top GO and KEGG enrichment of these 400 DEGs includes cell cycle, proteoglycans in cancer, p53 signaling pathway, protein digestion and absorption, transcriptional dysregulation in cancer, and oocyte meiosis, where 66 DEGs are in these six biological pathways, called GO-DEGs. In total, 32 DEMs downregulated these 66 GO-DEGs, where 22 DEMs were verified by different types of experiments in ESCC tissues, cells or serum from literature. For the other 10 DEMs, only hsa-miR-34b-3p showed no significant correlation with the overall survival of ESCC patients by single-factor cox regression analysis. Novel nine DEMs related to ESCC were: three down-regulated (hsa-miR-215-5p, hsa-miR-194-3p, hsa-miR-29b-2-5p), and six up-regulated (hsa-miR-944, hsa-miR-205-3p, hsa-miR-4652-5p, hsa-miR-452-3p, hsa-miR-6499-3p, and hsa-miR-767-5p).
Conclusion: This study identified nine novel miRNA markers potentially related to the diagnosis of ESCC and participated in the occurrence and development of ESCC through critical signaling pathways.
Introduction
Esophageal Squamous Cell Carcinoma (ESCC) is a highly aggressive malignancy with a particularly high incidence in China. Because early symptoms are often subtle, most patients are diagnosed at advanced stages, leading to a dismal five-year survival rate of only 15–25%.
While microRNAs (miRNAs)—small, non-coding RNAs that regulate gene expression—have long been recognized as potential cancer biomarkers, the complete "miRNA landscape" in ESCC remains partially understood. This study sought to identify specific miRNAs that actively drive the molecular pathogenesis of ESCC, distinguishing them from markers already well-documented in existing literature.
Methodology
The study employed a robust bioinformatic pipeline to cross-reference genomic data from The Cancer Genome Atlas (TCGA), comparing 94 ESCC tissue samples against 13 normal controls. Using the limma package in R, researchers identified Differentially Expressed miRNAs (DEMs) and Differentially Expressed Genes (DEGs).
To ensure biological relevance, the team used the miRTarBase database to predict target genes, focusing only on the "intersection"—genes that were both predicted targets and significantly dysregulated in the ESCC samples. Functional enrichment via Gene Ontology (GO) and KEGG pathway analysis was performed to identify the biological circuits disrupted by these miRNA-mRNA pairs. Finally, by searching miRNACancerMap and PubMed, the authors filtered out previously reported markers to isolate novel candidates.
Key Results
The analysis identified 48 DEMs (28 up-regulated, 20 down-regulated) and 1,319 DEGs. After filtering against known literature, nine miRNAs were identified as novel ESCC markers. These markers are categorized by their expression status and their specific target genes, which are involved in critical oncogenic pathways such as the cell cycle and p53 signaling.
The Nine Novel Markers:
- Up-regulated: hsa-miR-944, hsa-miR-205-3p, hsa-miR-4652-5p, hsa-miR-452-3p, hsa-miR-6499-3p, and hsa-miR-767-5p.
- Down-regulated: hsa-miR-215-5p, hsa-miR-194-3p, and hsa-miR-29b-2-5p.
These miRNAs regulate a complex network of genes. For instance, hsa-miR-944 targets BCL11B, while hsa-miR-215-5p is linked to a broad array of targets including KNL1, BUB1B, and WNT3, suggesting a central role in cell cycle regulation.
Discussion and Future Directions
The identification of these nine novel miRNAs expands the toolkit for researchers looking to develop diagnostic panels or targeted therapies for ESCC. The study's multi-omic approach provides strong evidence for a functional regulatory relationship between these miRNAs and the pathways driving ESCC proliferation.
However, as this study is primarily computational, these findings require experimental validation. Future work should involve clinical validation in independent patient cohorts using qPCR and functional assays (such as luciferase reporter assays or CRISPR knockouts) to confirm the direct regulation of predicted target genes in ESCC cell lines. Additionally, developing prognostic models based on these nine miRNAs could improve the accuracy of survival predictions and treatment responses for ESCC patients.
Summary updated